All Stories

  1. Prognostic Impact of Concomitant Genomic Alterations in FGFR2 ‐Positive Cholangiocarcinoma Treated With Pemigatinib

    Article • Liver International, July 2026, Wiley

    Dr Mohamed Bouattour

  2. Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma

    Article • JHEP Reports, June 2026, Elsevier

    Dr Mohamed Bouattour

  3. Second-Line TKI after First-Line Immunotherapy-based Treatment in Advanced HCC: Reconstructed IPD Meta-analysis

    Article • JHEP Reports, May 2026, Elsevier

    Dr Mohamed Bouattour

  4. Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data

    Article • Clinical Cancer Research, April 2026, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  5. Atezolizumab–Bevacizumab in Very Elderly With Hepatocellular Carcinoma: Age Alone Is Not a Limiting Factor Except in ALBI Grade 3

    Article • JHEP Reports, March 2026, Elsevier

    Dr Mohamed Bouattour

  6. Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma

    Article • Annals of Hepatology, December 2025, Elsevier

    Dr Mohamed Bouattour

  7. PSMA immunohistochemistry as a diagnostic biomarker of hepatocellular carcinoma

    Article • JHEP Reports, November 2025, Elsevier

    Dr Mohamed Bouattour

  8. Correction: ESR Bridges: imaging and treatment of uncommon liver tumours—a multidisciplinary view

    Article • European Radiology, October 2025, Springer Science + Business Media

    Dr Mohamed Bouattour

  9. Epidemiology, Clinical, Molecular Features, and Prognosis of Early-Onset Biliary Tract Cancer: A Systematic Review & Meta-Analysis

    Article • JHEP Reports, October 2025, Elsevier

    Dr Mohamed Bouattour

  10. Sunitinib as Second‐Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN ‐ CK GERCOR Phase II

    Article • Liver International, July 2025, Wiley

    Dr Mohamed Bouattour

  11. Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study

    Article • The Oncologist, June 2025, Oxford University Press (OUP)

    Dr Mohamed Bouattour

  12. Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies

    Article • JHEP Reports, June 2025, Elsevier

    Dr Mohamed Bouattour

  13. ESR Bridges: imaging and treatment of uncommon liver tumours—a multidisciplinary view

    Article • European Radiology, May 2025, Springer Science + Business Media

    Dr Mohamed Bouattour

  14. Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma

    Article • United European Gastroenterology Journal, July 2024, Wiley

    Dr Mohamed Bouattour

  15. ESR Bridges: imaging and treatment of hepatocellular carcinoma—a multidisciplinary view

    Article • European Radiology, March 2024, Springer Science + Business Media

    Dr Mohamed Bouattour

  16. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

    Article • European Journal of Cancer, March 2024, Elsevier

    Dr Mohamed Bouattour

  17. Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison

    Article • European Journal of Cancer, January 2024, Elsevier

    Dr Mohamed Bouattour

  18. Atezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study

    Article • United European Gastroenterology Journal, December 2023, Wiley

    Dr Mohamed Bouattour

  19. Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy

    Article • Hepatology Communications, September 2023, Wolters Kluwer Health

    Dr Mohamed Bouattour

  20. The Safety and Effectiveness of Hepatic Transarterial Embolic Locoregional Therapy in Patients with Contraindications to Hepatectomy after Portal Vein Embolization

    Article • Journal of Vascular and Interventional Radiology, August 2023, Elsevier

    Dr Mohamed Bouattour

  21. Improving pain control during transarterial chemoembolization for hepatocellular carcinoma performed under local anesthesia with multimodal analgesia

    Article • Diagnostic and Interventional Imaging, March 2023, Elsevier

    Dr Mohamed Bouattour

  22. Outcome of liver cancer patients with SARS‐CoV‐2 infection

    Article • Liver International, May 2022, Wiley

    Dr Mohamed Bouattour

  23. Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent

    Article • Diagnostic and Interventional Imaging, December 2021, Elsevier

    Dr Mohamed Bouattour

  24. Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion

    Article • Clinics and Research in Hepatology and Gastroenterology, November 2021, Elsevier

    Dr Mohamed Bouattour

  25. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

    Article • European Journal of Cancer, September 2021, Elsevier

    Dr Mohamed Bouattour

  26. Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas

    Article • JHEP Reports, August 2021, Elsevier

    Dr Mohamed Bouattour

  27. Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey

    Article • Clinics and Research in Hepatology and Gastroenterology, May 2021, Elsevier

    Dr Mohamed Bouattour

  28. Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI)

    Article • Clinics and Research in Hepatology and Gastroenterology, March 2021, Elsevier

    Dr Mohamed Bouattour

  29. Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240

    Article • Cancer, November 2020, Wiley

    Dr Mohamed Bouattour

  30. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Article • Journal of Clinical Oncology, January 2020, American Society of Clinical Oncology (ASCO)

    Dr Mohamed Bouattour

  31. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma

    Article • Clinical Pharmacokinetics, May 2019, Springer Science + Business Media

    Dr Mohamed Bouattour

  32. Management of immune-related adverse events resulting from immune checkpoint blockade

    Article • Expert Review of Anticancer Therapy, December 2018, Taylor & Francis

    Dr Mohamed Bouattour

  33. Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?—review of the open label phase III trial CONKO 005

    Article • HepatoBiliary Surgery and Nutrition, September 2018, AME Publishing Company

    Dr Mohamed Bouattour

  34. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance

    Article • Hepatology, May 2018, Wiley

    Dr Mohamed Bouattour

  35. Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?

    Article • Journal of Hepatology, May 2018, Elsevier

    Dr Mohamed Bouattour

  36. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma

    Article • Hepatology, February 2018, Wiley

    Dr Mohamed Bouattour

  37. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

    Article • The Lancet Oncology, October 2017, Elsevier

    Dr Mohamed Bouattour

  38. Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma

    Article • ESMO Open, October 2017, BMJ

    Dr Mohamed Bouattour

  39. LBA-001Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial

    Article • Annals of Oncology, June 2017, Oxford University Press (OUP)

    Dr Mohamed Bouattour

  40. Carcinome hépatocellulaire : nouveaux concepts, nouvelles molécules et nouvelles approches

    Article • ONCOLOGIE, June 2017, Lavoisier

    Dr Mohamed Bouattour

  41. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM

    Article • Trials, November 2016, Springer Science + Business Media

    Dr Mohamed Bouattour

  42. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study

    Article • International Journal of Nanomedicine, November 2016, Dove Medical Press

    Dr Mohamed Bouattour

  43. Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia

    Article • Medicine, November 2015, Wolters Kluwer Health

    Dr Mohamed Bouattour

  44. Abstract 221: Ex vivo cultures of freshly explanted tumors: a potent translational approach for screening novel targeted agents

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  45. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?

    Article • Journal of Clinical Oncology, August 2015, American Society of Clinical Oncology (ASCO)

    Dr Mohamed Bouattour

  46. Atypical Presentation of Hepatocellular Carcinoma Mimicking a Gastric Hepatoid Adenocarcinoma

    Article • Medicine, July 2015, Wolters Kluwer Health

    Dr Mohamed Bouattour

  47. Reply to M. Bouattour et al

    Article • Journal of Clinical Oncology, June 2015, American Society of Clinical Oncology (ASCO)

    Dr Mohamed Bouattour

  48. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy

    Article • World Journal of Hepatology, January 2015, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Mohamed Bouattour

  49. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging

    Article • World Journal of Hepatology, January 2015, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Mohamed Bouattour

  50. Abstract 3484: Ex-vivo cultures of freshly explanted tumor specimens (TIPCAN®), a potent translational approach for screening novel targeted agents

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  51. Molecular Targeted Drugs under Investigation in Hepatocellular Carcinoma

    Article • September 2014, Bentham Science Publishers

    Dr Mohamed Bouattour

  52. The Sorafenib for Hepatocellular Carcinoma (HCC) in Adjuvant Setting: The End of the Story was Already Written?

    Article • Gastroenterology & Hepatology Open Access, August 2014, MedCrave Group LLC

    Dr Mohamed Bouattour

  53. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies

    Article • Investigational New Drugs, April 2014, Springer Science + Business Media

    Dr Mohamed Bouattour

  54. P998 BENEFIT OF SORAFENIB ACCORDING TO UNDERLYING LIVER DISEASE ETIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

    Article • Journal of Hepatology, April 2014, Elsevier

    Dr Mohamed Bouattour

  55. Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

    Article • The Oncologist, March 2014, Alphamed Press

    Dr Mohamed Bouattour

  56. Intratumoral Gas in Hepatocellular Carcinoma following Transarterial Chemoembolization: Associated Factors and Clinical Impact

    Article • Journal of Vascular and Interventional Radiology, November 2013, Elsevier

    Dr Mohamed Bouattour

  57. Abstract C268: MET-inhibition using SU11274 and HER-inhibitions with lapatinib impair proliferation, motility and invasion in hepatocellular carcinoma (HCC) and exhibits an increased efficacy un sorafenib-tolerant model.

    Article • Molecular Cancer Therapeutics, November 2013, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  58. Biomarqueurs prédictifs d’efficacité

    Article • January 2013, Springer Science + Business Media

    Dr Mohamed Bouattour

  59. Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus

    Article • Pancreatology, November 2012, Elsevier

    Dr Mohamed Bouattour

  60. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib

    Article • Targeted Oncology, May 2012, Springer Science + Business Media

    Dr Mohamed Bouattour

  61. Thérapies ciblées dans le carcinome hépatocellulaire: indications et perspectives

    Article • ONCOLOGIE, March 2012, Lavoisier

    Dr Mohamed Bouattour

  62. Enjeux et spécificités de l’évaluation radiologique des tumeurs neuroendocrines pancréatiques traitées par les thérapies ciblées

    Article • Cancéro digest, January 2012, INIST-CNRS

    Dr Mohamed Bouattour

  63. Prospective evaluation of the management of hepatocellular carcinoma in the elderly

    Article • Digestive and Liver Disease, December 2011, Elsevier

    Dr Mohamed Bouattour

  64. Abstract B175: TGF- -RI kinase inhibitors LY2157299 and LY364947 decrease motility and invasion in hepatocarcinoma (HCC) cells developing resistance to VEGFR/PDGFR kinase inhibitors.

    Article • Molecular Cancer Therapeutics, November 2011, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  65. Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma

    Article • Journal of Hepatology, May 2011, Elsevier

    Dr Mohamed Bouattour

  66. Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

    Article • Clinical Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  67. Novel molecular therapies in hepatocellular carcinoma

    Article • Liver International, January 2011, Wiley

    Dr Mohamed Bouattour

  68. Prise en charge des tumeurs primitives du foie et des voies biliaires

    Article • January 2011, Springer Science + Business Media

    Dr Mohamed Bouattour

  69. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

    Article • European Journal of Gastroenterology & Hepatology, September 2010, Wolters Kluwer Health

    Dr Mohamed Bouattour

  70. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development

    Article • Expert Opinion on Drug Metabolism & Toxicology, July 2010, Informa Healthcare

    Dr Mohamed Bouattour

  71. Thérapies ciblées dans le carcinome hépatocellulaire

    Article • La Presse Médicale, July 2010, Elsevier

    Dr Mohamed Bouattour

  72. Les nouveaux antiangiogéniques : état de la recherche

    Article • Cancéro digest, January 2010, INIST-CNRS

    Dr Mohamed Bouattour

  73. Les antiangiogéniques dans le carcinome hépatocellulaire en dix questions

    Article • Cancéro digest, January 2010, INIST-CNRS

    Dr Mohamed Bouattour

  74. Sunitinib in Hepatocellular Carcinoma: Redefining Appropriate Dosing, Schedule, and Activity End Points

    Article • Journal of Clinical Oncology, December 2009, American Society of Clinical Oncology (ASCO)

    Dr Mohamed Bouattour

  75. Feeding Soybean Oil to Dairy Goats Increases Conjugated Linoleic Acid in Milk

    Article • Journal of Dairy Science, June 2008, American Dairy Science Association

    Dr Mohamed Bouattour

  76. Atteinte palpébrale au cours d'un syndrome de Löfgren

    Article • La Revue de Médecine Interne, June 2003, Elsevier

    Dr Mohamed Bouattour